Alector, Inc.
Alector, Inc. (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases with high unmet medical needs. The company's website is www.alector.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Alector, Inc. does
In the company’s own words
Alector, Inc. (NASDAQ: ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases with high unmet medical needs. The company's website is www.alector.com.
Alector's core business centers on discovering and developing innovative treatments that address disease through targeted mechanisms, including removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function. The company's work is informed by advances in disease biology, particularly the roles of misfolded or deficient proteins, lysosomal dysfunction, and immune and neuronal pathway disruption.
The company's clinical pipeline is anchored by nivisnebart, a progranulin-elevating monoclonal antibody currently in Phase 2 development for early Alzheimer's disease under a collaboration with GlaxoSmithKline. Nivisnebart completed enrollment in the PROGRESS-AD trial in April 2025, with trial completion expected in 2026. This program represents Alector's most advanced asset, developed through a strategic alliance established in July 2021 that provided the company with $700 million in upfront payments and potential milestone payments up to $1.5 billion.
Beyond its clinical program, Alector maintains a robust preclinical and research pipeline leveraging its proprietary Alector Brain Carrier (ABC) platform, a blood-brain barrier delivery technology designed to improve central nervous system exposure across multiple therapeutic modalities. The ABC platform supports development of candidates including AL137, an anti-amyloid beta antibody for Alzheimer's disease; AL050, a glucocerebrosidase enzyme replacement therapy for Parkinson's disease and Lewy body dementia; and multiple siRNA programs targeting tau, alpha-synuclein, and NLRP3 for various neurodegenerative conditions.
Alector's competitive advantages stem from its expertise in neuroscience, protein engineering, and antibody discovery, combined with its proprietary ABC platform technology. The company employs a research and discovery engine that identifies genetically validated targets, utilizes biomarkers for patient selection, and applies advanced biologics discovery approaches. The company relies on third-party contract development and manufacturing organizations for production of its product candidates and does not currently maintain internal manufacturing capabilities.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1653087
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Alector, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Alector, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Alector, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Alector, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Alector, Inc.'s last four quarterly filings that the numbers alone won't show?”